Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

被引:71
|
作者
Schiffmann, R
Rapkiewicz, A
Abu-Asab, M
Ries, M
Askari, H
Tsokos, M
Quezado, M
机构
[1] NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
关键词
Fabry disease; lysosomes; atherosclerosis; myocardial infarction; enzyme replacement therapy; glycolipids;
D O I
10.1007/s00428-005-0089-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We describe the postmortem findings of a 47-year-old man with Fabry disease, an X-linked glycolipid storage disorder, who was on enzyme replacement therapy with recombinant alpha-galactosidase A for more than 2 years. The patient had widespread atherosclerotic coronary artery disease that culminated in a massive acute myocardial infarction. Atherosclerotic lesions were seen in the right and left coronary systems, aorta, and the basilar artery. Typical Fabry cardiomyopathy and glomerular nephropathy were found. With the exception of vascular endothelial cells, extensive glycolipid storage deposits were seen in all vascular and nonvascular cells and organ systems. We conclude that, at least in this patient, repeated infusions with alpha-galactosidase A over a prolonged period did not appreciably clear storage material in cells other than vascular endothelial cells. These findings also illustrate accelerated atherosclerosis in susceptible patients with Fabry disease.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 50 条
  • [31] Manifestation of Fabry disease in a heterozygous female patient: new perspectives arising from enzyme replacement therapy
    Jansen, T.
    Brokalaki, E.
    Hillen, U.
    Hentschke, M.
    Grabbe, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2006, 131 (28-29) : 1590 - 1593
  • [32] Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease
    Lenders, Malte
    Nowak, Albina
    Cybulla, Markus
    Kaufeld, Jessica
    Koehn, Anja Friederike
    Muschol, Nicole Maria
    Kurschat, Christine
    Brand, Eva
    ORPHANET JOURNAL OF RARE DISEASES, 2025, 20 (01)
  • [33] Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey
    Ramaswami, U.
    Parini, R.
    Pintos-Morell, G.
    Kalkum, G.
    Kampmann, C.
    Beck, M.
    CLINICAL GENETICS, 2012, 81 (05) : 485 - 490
  • [34] Fabry nephropathy: 5 years of enzyme replacement therapy-a short review
    Barbey, Frederic
    Lidove, Olivier
    Schwarting, Andreas
    CLINICAL KIDNEY JOURNAL, 2008, 1 (01): : 11 - 19
  • [35] Characteristic cardiac capillary pericytes in a Fabry disease patient receiving enzyme replacement therapy
    Kanamori, Hiromitsu
    Nakashima, Takashi
    Yoshida, Akihiro
    Miyazaki, Tatsuhiko
    Mikami, Atsushi
    Okura, Hiroyuki
    HELLENIC JOURNAL OF CARDIOLOGY, 2024, 75 : 101 - 102
  • [36] Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era
    Karras, A.
    De Lentdecker, P.
    Delahousse, M.
    Debauchez, M.
    Tricot, L.
    Pastural, M.
    Bruneval, P.
    Zemoura, L.
    Van Huyen, J. -P. Duong
    Lidove, O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (06) : 1345 - 1348
  • [37] Fabry disease in Spain:: first analysis of the response to enzyme replacement therapy
    Rivera Gallego, Alberto
    Lopez Rodriguez, Monica
    Barbado Hernandez, Francisco Javier
    Barba Romero, Miguel Angel
    Garcia de Lorenzo y Mateos, Abelardo
    Pintos Morell, Guillen
    MEDICINA CLINICA, 2006, 127 (13): : 481 - 484
  • [38] Fabry disease:: demographic data since introduction of enzyme replacement therapy
    Cybulla, M.
    Walter, K.
    Neumann, H. P. H.
    Widmer, U.
    Schaerer, M.
    Sunder-Plassmann, G.
    Jansen, T.
    Rolfs, A.
    Beck, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2007, 132 (28-29) : 1505 - 1509
  • [39] The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease
    Morell, Chantal F.
    Clarke, Joe T. R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (05) : 631 - 639
  • [40] Gastrointestinal manifestations of Fabry disease: Clinical response to enzyme replacement therapy
    Banikazemi, M
    Ullman, T
    Desnick, RJ
    MOLECULAR GENETICS AND METABOLISM, 2005, 85 (04) : 255 - 259